Hepatotoxicity from first line antiretroviral therapy: An experience from a resource limited setting

African Health Sciences

Volumn 11, Issue 1, 2011, Pages 16-23

  Kalyesubula, Robert ^a   Kagimu, M ^a   Opio, K C ^a   Kiguba, R ^a   Semitala, C F ^a   Schlech, W F ^b   Katabira, E T ^a  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

HAART; Hepatotoxicity; Uganda

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; ETHAMBUTOL; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LIVER ENZYME; UNCLASSIFIED DRUG;

ACUTE HEPATITIS; ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER; MALE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; UGANDA;

EID: 79953769415     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. Aids. 2002; 5; 16(10):1363-70.
2. Weidle PJ, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugyenyi P, Mermin J, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet Infect Dis. 2002; 6(360(9326):34-40.
3. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005; 15;191(6):825-9.
4. Katabira ET, Kamya MR (Eds). National antiretroviral treatment and care guidelines for adults and children. In: MOH, 2nd ed: STD/AIDS Control Programme, Uganda; 2008.
5. Forna F LC, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, et al. Clinical toxicity of highly active antiretroviral therapy in home-based-AIDS care program in rural Uganda. J acquir Imm Def Syndr. 2007; 44:456-62.
6. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Aids. 2007; 19; 21(10):1301-8.
7. Pol S, Lebray P, Vallet PA. HIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic Mechanisms. Clin Inf Dis. 2004;38(S2):S65-S72.
8. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002; 1;186(1):23-31.
9. Justice AC, Wagner JH, Fusco GP. HIV survival: liver function tests independently predict survival. XIV International AIDS Conference; 2002; Barcelona); 2002.
10. Hahn JA, Maier M, Byakika-Tusiime J, Oyugi JH, Bangsberg DR. Hepatotoxicity during nevirapinebased fixed-dose combination antiretroviral therapy in Kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic Ill). 2007; 6(2):83-6.
11. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. Aids. 2008; 12;22(17):2303-11.
12. Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A, et al. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010;21(8):553-7.
13. Dieterich DT, Patrick AR, Love J. Drug-induced liver injury associated with the use of non nucleoside reversetranscriptase inhibitors. Clin Inf Dis 2004; 38:S80-S9.
14. Bottaro EG, Huberman MJ, Iannella Mdel C, Vesperoni FA, Scapellato PG, Errea S, et al. Nevirapineassociated toxicity in clinical practice in Buenos Aires, Argentina. J Int Assoc Physicians AIDS Care (Chic Ill). 2009; 9(5):306-12.
15. Servin-Abad L ME, Baracco G, Arosemena L, Regev A, Jeffers L, Schiff E. Liver enzymes elevation after HAART in HIV-HCV co-infection. Journal of Viral Hepatitis. 2005; 12(4):429-34.
16. Seremba E, Ocama P, Opio CK, Kagimu M, Yuan HJ, Attar N, et al. Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol. 2010; 82(8):1334-40.
17. Seremba E, Ocama P, Opio CK, Kagimu M, Thomas DL, Yuan HJ, et al. Poor performance of hepatitis C antibody tests in hospital patients in Uganda. J Med Virol. 2010; 82(8):1371-8.
18. Castelnuovo B, Nanyonjo A, Kamya M, Ocama P. Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia? Afr Health Sci. 2008; 8(2):133-4.
19. Navarro VJ, Senior JR. Drug-Related Hepatotoxicity. N Engl J Med. 2006; 354:731-9.
20. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010.
21. Sayana S, Manchanda R, Khanlou H, Saavedra J, Reis P, Weinstein M. DART and laboratory monitoring of HIV treatment. Lancet. 2010; 20;375(9719):979; author reply-80.
22. Peter T, Blair D, Reid M, Justman J. DART and laboratory monitoring of HIV treatment. Lancet. 2010; 20;375(9719):979.
23. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, et al. Anti-tuberculosis therapyinduced hepatotoxicity among Ethiopian HIVpositive and negative patients. PLoS ONE. 2008;3(3):e1809.
24. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury following the introduction of HAART. J Acquir Imm Def Syndr. 2001; 27:426-31.
25. Martínez E, Blanco J, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM. Hepatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-8.